In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital

Medical Mycology

Volumn 43, Issue 2, 2005, Pages 171-178

  Arikan, Sevtap ^a   Sancak, Banu ^a   Hascelik, Gulsen ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Amphotericin B; Candida; Caspofungin; Fluconazole; Itraconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL; YARROWIA LIPOLYTICA;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; HOSPITALS, UNIVERSITY; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; TURKEY;

CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CICONIIFORMES;

EID: 15944374266     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780410001731565     Document Type: Article

References (43)

1. Dupont B. Caspofungin: new echinocandin antifungal agent. J Mycol Med 2002; 12: S20-S24.
2. Datry A, Thellier M. Echinocandins: a new class of antifungal agents, a new mechanism of action. J Mycol Med 2002; 12: S5-S9.
3. Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61 1121-1129.
4. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Invest Drugs 2001; 10: 269-280.
5. Groll AH, Walsh TJ. Caspofangin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Invest Drugs 2001; 10: 1545-1558.
6. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-3844.
7. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45: 327-330.
8. Arikan S, Paetznick V, Rex JH. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2002; 46: 3084-3087.
9. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247.
10. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-3012.
11. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41: 1835-1836.
12. Douglas CM, Bowman JC, Abruzzo GK, et al. The glucan synthesis inhibitor caspofungin acetate (Cancidas, MK-0991, L-743872) kills Aspergillus fumigatus hyphal tips in vitro and is efficacious against disseminated aspergillosis in cyclophosphamide-induced chronically leukopenic mice, Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada, 17-20 September 2000, ASM Press Washington, DC, USA. (Abstract no.1683.)
13. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46: 3634-3636.
14. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40: 2228-2230.
15. Bartizal K, Motyl M, Hicks P, et al. In vitro susceptibility results and correlation with outcome: Results from the randomized invasive candidiasis (ic) study of caspofungin vs. amphotericin B. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 27-30 September 2000, ASM Press Washington, DC, USA. (Abstract no. M-1240.)
16. Ju JY, Polhamus C, Marr KA, Holland SM, Bennett JE. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice. Antimicrob Agents Chemother 2002; 46: 1240-1245.
17. Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofangin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31: 183-187.
18. Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003; 41: 5729-5731.
19. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000; 182: 1791-1795.
20. Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002; 35: E35-E36.
21. Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice, Antimicrob Agents Chemother 2000; 44: 2310-2318.
22. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-457.
23. Chocarro MA, Gonzalez A, Garcia I. Caspofungin versus amphotericin B for the treatment of candidal esophagitis. Clin Infect Dis 2002; 35: 107-108.
24. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
25. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-1535.
26. Bernard EM, Ishimaru T, Armstrong D. Low doses of the pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulmonary aspergillosis. In: Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Che motherapy, New Orleans, USA, 15-18 September 2000, ASM Press Washington, DC, USA.
27. Caillot D. Invasive aspergillosis/therapeutic aspects: caspofungin. J Mycol Med 2002; 12: S18-S19.
28. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42: 1985-1989.
29. Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001; 45: 1854-1859.
30. Larone D. Medically Important Fungi - A Guide to Identification. Washington, DC: ASM Press, 1995.
31. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard NCCLS document M27-A2. Wayne, PA: NCCLS, 2002.
32. Waldrep TW, Keiser P, Ware A, et al. Failure of intermittent caspofungin therapy to treat fluconazole-resistant mucocutaneous Candida despite apparent in vitro susceptibility. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 27-30 September 2000, ASM Press Washington, DC, USA. (Abstract no. M-891.)
33. Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41: 1957-1960.
34. Lozano-Chiu M, Nelson PW, Paetznick VL, Rex JH. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. J Clin Microbiol 1999; 37: 1625-1627.
35. Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 2001; 39: 4387-4389.
36. Laverdiere M, Restieri C, Habel F. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of E-test and NCCLS reference methods. Int J Antimicrob Agents 2002; 20: 468-471.
37. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956.
38. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47; 2003: 3149-3154.
39. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-2332.
40. Vazquez JA, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species, Antimicrob Agents Chemother 1997; 41: 1612-1614.
41. Ostrosky-Zeichner L, Matar M, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 27-30 September 2000, ASM Press, Washington, DC, USA. (Abstract no. M-1816.)
42. St Germain G. Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans. Antimicrob Agents Chemother 1990; 34: 2304-2306.
43. Uzun O, Arikan S, Kocagoz S, Sancak B, Unal S. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis 2000; 38: 101-107.